tiprankstipranks
Trending News
More News >
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
US Market

Alnylam Pharma (ALNY) Stock Forecast & Price Target

Compare
1,239 Followers
See the Price Targets and Ratings of:

ALNY Analyst Ratings

Strong Buy
23Ratings
Strong Buy
19 Buy
4 Hold
0 Sell
Based on 23 analysts giving stock ratings to
Alnylam
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ALNY Stock 12 Month Forecast

Average Price Target

$327.95
▲(13.05%Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is $327.95 with a high forecast of $500.00 and a low forecast of $245.00. The average price target represents a 13.05% change from the last price of $290.10.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"$147","324":"$324","501":"$501","235.5":"$235.5","412.5":"$412.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$500.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":327.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$327.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":245,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$245.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,235.5,324,412.5,501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,255.13,273.9661538461538,292.8023076923077,311.6384615384615,330.4746153846154,349.3107692307692,368.14692307692303,386.9830769230769,405.8192307692308,424.6553846153846,443.4915384615384,462.3276923076923,481.1638461538461,{"y":500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,255.13,260.73153846153843,266.33307692307693,271.93461538461537,277.53615384615387,283.1376923076923,288.73923076923074,294.34076923076924,299.9423076923077,305.5438461538462,311.1453846153846,316.74692307692305,322.34846153846155,{"y":327.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,255.13,254.35076923076923,253.57153846153847,252.7923076923077,252.0130769230769,251.23384615384614,250.45461538461538,249.67538461538462,248.89615384615385,248.1169230769231,247.3376923076923,246.55846153846153,245.77923076923076,{"y":245,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":149.96,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.43,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.32,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":268.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":262.69,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":276.06,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 62,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":273.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":253.01,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":235.31,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":271.31,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.75,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":255.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$500.00Average Price Target$327.95Lowest Price Target$245.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ALNY
TipRanks AITipRanks
Not Ranked
TipRanks
$286
Hold
-1.41%
Downside
Reiterated
05/13/25
Alnylam Pharmaceuticals scores 62, reflecting its robust revenue growth and promising future prospects in the biotechnology sector. While strong liquidity and strategic growth initiatives are positives, the company faces significant challenges with profitability, high leverage, and valuation metrics. The earnings call highlights a positive outlook, yet regulatory uncertainties and R&D expenses pose ongoing risks. Technical analysis supports a neutral to positive trend, but the negative P/E ratio underscores financial challenges.
J.P. Morgan Analyst forecast on ALNY
Jessica FyeJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/25
Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
Barclays Analyst forecast on ALNY
Gena WangBarclays
Barclays
$329
Buy
13.41%
Upside
Reiterated
05/27/25
Alnylam Pharma (ALNY) Receives a Buy from Barclays
TD Cowen Analyst forecast on ALNY
Ritu BaralTD Cowen
TD Cowen
$371
Buy
27.89%
Upside
Reiterated
05/19/25
TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Citi
$351$364
Buy
25.47%
Upside
Reiterated
05/19/25
Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements
Stifel Nicolaus Analyst forecast on ALNY
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$345
Buy
18.92%
Upside
Reiterated
05/14/25
Stifel Nicolaus Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on ALNY
Liisa BaykoEvercore ISI
Evercore ISI
$280
Buy
-3.48%
Downside
Reiterated
05/06/25
Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)
BMO Capital Analyst forecast on ALNY
Kostas BiliourisBMO Capital
BMO Capital
$300
Buy
3.41%
Upside
Reiterated
05/06/25
Alnylam Pharma's Strong Market Position and Amvuttra's Impressive Sales Growth Drive Buy Recommendation
H.C. Wainwright Analyst forecast on ALNY
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$500
Buy
72.35%
Upside
Reiterated
05/05/25
Alnylam Pharma's Strong Commercial Momentum and Promising Pipeline Justify Buy Rating and $500 Price Target
Chardan Capital Analyst forecast on ALNY
Keay NakaeChardan Capital
Chardan Capital
$300$325
Buy
12.03%
Upside
Reiterated
05/02/25
Alnylam Pharma (ALNY) Gets a Buy from Chardan Capital
Scotiabank Analyst forecast on ALNY
Greg HarrisonScotiabank
Scotiabank
$342
Buy
17.89%
Upside
Reiterated
05/02/25
Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
UBS
$331$349
Buy
20.30%
Upside
Reiterated
05/02/25
Alnylam price target raised to $349 from $331 at UBSAlnylam price target raised to $349 from $331 at UBS
Piper Sandler Analyst forecast on ALNY
Edward TenthoffPiper Sandler
Piper Sandler
$304
Buy
4.79%
Upside
Reiterated
05/02/25
Piper Sandler Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Canaccord Genuity Analyst forecast on ALNY
Whitney IjemCanaccord Genuity
Canaccord Genuity
$390
Buy
34.44%
Upside
Reiterated
05/01/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: American Well (NYSE: AMWL), Alnylam Pharma (NASDAQ: ALNY) and Teleflex (NYSE: TFX)
William Blair Analyst forecast on ALNY
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/01/25
Alnylam Pharma: Strong Financial Performance and Promising Growth Catalysts Justify Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on ALNY
TipRanks AITipRanks
Not Ranked
TipRanks
$286
Hold
-1.41%
Downside
Reiterated
05/13/25
Alnylam Pharmaceuticals scores 62, reflecting its robust revenue growth and promising future prospects in the biotechnology sector. While strong liquidity and strategic growth initiatives are positives, the company faces significant challenges with profitability, high leverage, and valuation metrics. The earnings call highlights a positive outlook, yet regulatory uncertainties and R&D expenses pose ongoing risks. Technical analysis supports a neutral to positive trend, but the negative P/E ratio underscores financial challenges.
J.P. Morgan Analyst forecast on ALNY
Jessica FyeJ.P. Morgan
J.P. Morgan
Buy
Reiterated
05/27/25
Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
Barclays Analyst forecast on ALNY
Gena WangBarclays
Barclays
$329
Buy
13.41%
Upside
Reiterated
05/27/25
Alnylam Pharma (ALNY) Receives a Buy from Barclays
TD Cowen Analyst forecast on ALNY
Ritu BaralTD Cowen
TD Cowen
$371
Buy
27.89%
Upside
Reiterated
05/19/25
TD Cowen Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)
Citi
$351$364
Buy
25.47%
Upside
Reiterated
05/19/25
Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements
Stifel Nicolaus Analyst forecast on ALNY
Paul MatteisStifel Nicolaus
Stifel Nicolaus
$345
Buy
18.92%
Upside
Reiterated
05/14/25
Stifel Nicolaus Keeps Their Buy Rating on Alnylam Pharma (ALNY)
Evercore ISI Analyst forecast on ALNY
Liisa BaykoEvercore ISI
Evercore ISI
$280
Buy
-3.48%
Downside
Reiterated
05/06/25
Evercore ISI Keeps Their Buy Rating on Alnylam Pharma (ALNY)
BMO Capital Analyst forecast on ALNY
Kostas BiliourisBMO Capital
BMO Capital
$300
Buy
3.41%
Upside
Reiterated
05/06/25
Alnylam Pharma's Strong Market Position and Amvuttra's Impressive Sales Growth Drive Buy Recommendation
H.C. Wainwright Analyst forecast on ALNY
Patrick TrucchioH.C. Wainwright
H.C. Wainwright
$500
Buy
72.35%
Upside
Reiterated
05/05/25
Alnylam Pharma's Strong Commercial Momentum and Promising Pipeline Justify Buy Rating and $500 Price Target
Chardan Capital Analyst forecast on ALNY
Keay NakaeChardan Capital
Chardan Capital
$300$325
Buy
12.03%
Upside
Reiterated
05/02/25
Alnylam Pharma (ALNY) Gets a Buy from Chardan Capital
Scotiabank Analyst forecast on ALNY
Greg HarrisonScotiabank
Scotiabank
$342
Buy
17.89%
Upside
Reiterated
05/02/25
Scotiabank Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
UBS
$331$349
Buy
20.30%
Upside
Reiterated
05/02/25
Alnylam price target raised to $349 from $331 at UBSAlnylam price target raised to $349 from $331 at UBS
Piper Sandler Analyst forecast on ALNY
Edward TenthoffPiper Sandler
Piper Sandler
$304
Buy
4.79%
Upside
Reiterated
05/02/25
Piper Sandler Sticks to Its Buy Rating for Alnylam Pharma (ALNY)
Canaccord Genuity Analyst forecast on ALNY
Whitney IjemCanaccord Genuity
Canaccord Genuity
$390
Buy
34.44%
Upside
Reiterated
05/01/25
Analysts Have Conflicting Sentiments on These Healthcare Companies: American Well (NYSE: AMWL), Alnylam Pharma (NASDAQ: ALNY) and Teleflex (NYSE: TFX)
William Blair Analyst forecast on ALNY
Myles MinterWilliam Blair
William Blair
Buy
Reiterated
05/01/25
Alnylam Pharma: Strong Financial Performance and Promising Growth Catalysts Justify Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alnylam Pharma

1 Month
xxx
Success Rate
15/26 ratings generated profit
58%
Average Return
+0.52%
reiterated a xxx
rating 14 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.69% of your transactions generating a profit, with an average return of +0.52% per trade.
3 Months
xxx
Success Rate
20/30 ratings generated profit
67%
Average Return
+8.49%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +8.49% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
27/30 ratings generated profit
90%
Average Return
+30.06%
reiterated a buy rating 9 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +30.06% per trade.
2 Years
xxx
Success Rate
20/20 ratings generated profit
100%
Average Return
+38.84%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +38.84% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALNY Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
5
6
8
9
6
Buy
22
28
48
48
50
Hold
8
6
10
14
12
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
36
40
66
71
68
In the current month, ALNY has received 56 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 327.95.
Each month's total comprises the sum of three months' worth of ratings.

ALNY Financial Forecast

ALNY Earnings Forecast

Next quarter’s earnings estimate for ALNY is -$0.67 with a range of -$1.34 to $0.70. The previous quarter’s EPS was -$0.44. ALNY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.
Next quarter’s earnings estimate for ALNY is -$0.67 with a range of -$1.34 to $0.70. The previous quarter’s EPS was -$0.44. ALNY beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.23% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.

ALNY Sales Forecast

Next quarter’s sales forecast for ALNY is $632.61M with a range of $562.00M to $704.00M. The previous quarter’s sales results were $594.19M. ALNY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.68% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.
Next quarter’s sales forecast for ALNY is $632.61M with a range of $562.00M to $704.00M. The previous quarter’s sales results were $594.19M. ALNY beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.68% of the time in the same period. In the last calendar year ALNY has Outperformed its overall industry.

ALNY Stock Forecast FAQ

What is ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharmaceuticals’s 12-month average price target is 327.95.
    What is ALNY’s upside potential, based on the analysts’ average price target?
    Alnylam Pharmaceuticals has 13.05% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ALNY a Buy, Sell or Hold?
          Alnylam Pharmaceuticals has a consensus rating of Strong Buy which is based on 19 buy ratings, 4 hold ratings and 0 sell ratings.
            What is Alnylam Pharmaceuticals’s price target?
            The average price target for Alnylam Pharmaceuticals is 327.95. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $500.00 ,the lowest forecast is $245.00. The average price target represents 13.05% Increase from the current price of $290.1.
              What do analysts say about Alnylam Pharmaceuticals?
              Alnylam Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of ALNY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis